Targeted Oncology Therapeutics


targeted oncology therapeutics
targeted oncology therapeutics

Targeted Oncology Therapeutics  • February 2020 •  TJK353F •  Price US $4,850


A number of factors are changing the way market participants view the cancer therapeutics market. These factors are evident in the disease targets and drug classes that comprise a significant number of recent trials. After decades of disappointment and missed financial objectives, the genetic underpinnings of disease are converging with improved computer-assisted pharmacological decision making. Market sector participants now find themselves pursuing realistic therapeutic strategies that have the potential to fulfill product strategies in both scientific and human terms.

Bar_Graph Targeted Oncology Therapeutics – Report Details (Download PDF)

Blue document  Targeted Oncology Therapeutics Report Order Form (Download PDF)


   Order Online



What You Will Learn

  • What is the market share of approved therapeutics?
  • What is the global supply picture for targeted therapeutics?
  • Who are the market leaders, by Indication? by Product?
  • What is the therapeutic coverage across all oncology indications? What are the product opportunities?
  • What are the established products in this space? by target, indication, API class, revenue?
  • What is the competitive picture for the major Oncology market segments?   
  •     Drug treatment resources
  •     Competitive therapy map
  •     Clinical trial activity
  • Who are the leading competitors in the field of next-generation therapeutics?

Targeted Oncology Therapeutics – Summary of Contents


The Recombinant Drug Ecosystem

Targeted Oncology Therapeutics Market Leaders

Oncology Biologics – Competitive Considerations

Approved Drugs for targeted Oncology Therapeutics

FDA-approved Drugs

EMA-approved Drugs

Biosimilars of Trastuzumab

EMA Approved Biosimilars

The Impact of Litigation on Biosimilar Product Launches

Targeted Oncology Therapeutics – Market Segments

Breast Cancers

Colorectal Cancers

Hematology Cancers

Lung Cancers


Metastatic Gastric Cancers

Neurological Cancers

Renal Cell Carcinomas

Urothelial Cancers

Supplier Competitive Assessments